FORM	4
------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Jacques Rachelle Suzanne				· ·		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
	3. Date of Earliest Transaction (Month/Day/Year) 06/17/2021						Officer (give title below) Officer (give title below)	her (specify belo	ow)	
	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
Date	Execution Date, if any	Code	ion V	(A) or Di	(A) or	of (D)	Owned Following Reported Transaction(s) (Instr. 3 and 4)	Ownership Form: Direct (D) or Indirect	Beneficial Ownership	
	(Middle) (Zip) 2. Transaction Date	Corbus Pharmac (Middle) 3. Date of Earliest Tr 06/17/2021 4. If Amendment, Da (Zip) 2. Transaction Date 2A. Deemed Execution Date, if	Corbus Pharmaceuticals H (Middle) 3. Date of Earliest Transaction (1006/17/2021) (Zip) 4. If Amendment, Date Original (Zip) Table I - No 2. Transaction Date (Month/Day/Year) 3. Transact Code (Instr. 8)	Corbus Pharmaceuticals Holdi (Middle) 3. Date of Earliest Transaction (Mont 06/17/2021 4. If Amendment, Date Original Filed (Zip) ZA. Deemed 2. Transaction Date (Month/Day/Year) S. Transaction Code (Instr. 8)	Corbus Pharmaceuticals Holdings, Inc. (Middle) 3. Date of Earliest Transaction (Month/Day/Year) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) (Middle) 4. If Amendment, Date Original Filed(Month/Day/Year) (Zip) Table I - Non-Derivative S 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction (A) or Di (Instr. 3) (Month/Day/Year) (Month/Day/Year) 4. Securi	(Middle) 3. Date of Earliest Transaction (Month/Day/Year) 06/17/2021 4. If Amendment, Date Original Filed(Month/Day/Year) (Zip) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquication (A) or Disposed of (Instr. 8) (Month/Day/Year)	Corbus Pharmaceuticals Holdings, Inc. [CRBP] (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 06/17/2021 4. If Amendment, Date Original Filed(Month/Day/Year) (Zip) Table I - Non-Derivative Securities Acqu 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	(Middle) 3. Date of Earliest Transaction (Month/Day/Year) (Check all applicat X_Director (Middle) 3. Date of Earliest Transaction (Month/Day/Year) (Check all applicat X_Director (Middle) 3. Date of Earliest Transaction (Month/Day/Year) (Check all applicat Month/Day/Year) (Zip) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing/Chec X_Form filed by One Reporting Person Form filed by More than One Reporting Person Form filed by More than One Reporting Person (Zip) Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) any (Month/Day/Year) 5. Amount of Securities Beneficially Own (A) or Disposed of (D) (Instr. 8) 2. Transaction Date (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	(Middle) 3. Date of Earliest Transaction (Month/Day/Year) 06/17/2021 (Check all applicable) 2. Transaction 06. Individual or Joint/Group FilingCheck Applicable Li X_form filed by One Reporting Person Form filed by More than One Reporting Person (Zip) Z A. Deemed Execution Date, if (Month/Day/Year) 3. Transaction (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Amount of Securities Beneficially Owned Following Reported Transaction(s) 6. Mount of Securities Beneficially Owned Following Reported Transaction(s)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained SEC 1474 (9-02)
in this form are not required to respond unless the form
displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
	Conversion	Date (Month/Day/Year)	Execution Date, if	Code	tion)	5. Numbo of Deriva Securitie Acquired or Dispos of (D) (Instr. 3, and 5)	ntive s l (A) sed	Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s)	Derivative Security: Direct (D) or Indirect	Beneficial
				Code	v	(A)		Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (right to buy)	\$ 2.07	06/17/2021		А		58,200		<u>(1)</u>	06/17/2031	Common Stock	58,200	\$ 0	58,200	D	
Stock Option (right to buy)	\$ 2.07	06/17/2021		А		58,200		(2)	06/17/2031	Common Stock	58,200	\$ 0	58,200	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Jacques Rachelle Suzanne 500 RIVER RIDGE DRIVE NORWOOD, MA 02062	Х						

Signatures

/s/ Sean Moran, attorney-in-fact for Rachelle Jacques	06/17/2021
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- (1) The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant.
- (2) Represents a special retention award comprised of options to purchase common stock. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).